Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVERT- Breast Cancer
NCT05384119Phase 1Terminated
- Sponsor
- Tvardi Therapeutics
- Start
- Jan 2023
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tti-101 in breast cancer (2 arms), sponsored by Tvardi Therapeutics. Primary endpoints: Dose Limiting Toxicity at 28 days, Adverse Event at 17 months and 2 more. Started Jan 2023; status: terminated.
02
Drugs
tti-101
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05384119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05384119.